WHO: Progress Has Stalled In Worldwide Effort To Eliminate Malaria
In other public health news, many Americans still live with the AIDS virus for years without realizing they have it; running doesn't necessarily help the heart; what happens when clinical trials fail; and abortion doulas.
Los Angeles Times:
The World Is Off Track In Its Goal To Eliminate Malaria. Here's Why.
Progress toward the global elimination of malaria has stalled, according to a report to be published Wednesday by the World Health Organization. The world made big gains against malaria from 2000 to 2015, with annual infections falling 18% and annual deaths dropping 48%. The WHO was so encouraged by the declines that in 2015 it announced a goal of cutting malaria infections and deaths worldwide by at least 40% by 2020. (Simmons, 11/28)
Los Angeles Times:
About 15% Of Americans With HIV Don't Know They're Infected, CDC Report Says
Half of the Americans recently diagnosed with HIV had been living with the virus for at least three years without realizing it, missing out on opportunities for early treatment and in some cases spreading it to others, according to a new report by the Centers for Disease Control and Prevention. (Healy, 11/28)
The New York Times:
How Running May Or May Not Help The Heart
If 50 men run 3,510 marathons over the course of three decades, will their heart health suffer or improve? A new study delving into precisely that question concludes that the answer is simultaneously reassuring and complicated, with long years of endurance training seeming not to harm runners’ hearts, but also not necessarily to benefit them in the ways that the runners themselves probably expected. (Reynolds, 11/29)
The New York Times:
A Failure To Heal
What happens when a clinical trial fails? This year, the Food and Drug Administration approved some 40 new medicines to treat human illnesses, including 13 for cancer, three for heart and blood diseases and one for Parkinson’s. We can argue about which of these drugs represent transformative advances (a new medicine for breast cancer, tested on women with relapsed or refractory disease, increased survival by just a few months; a drug for a type of leukemia had a more lasting impact), but we know, roughly, the chain of events that unfolds when a trial is positive. ... Yet the vastly more common experience in the life of a clinical scientist is failure: A pivotal trial does not meet its expected outcome. What happens then? (Mukherjee, 11/28)
The Washington Post:
The Long Five Minutes: Abortion Doulas Bring Comfort During A Complicated Time
“Do you support reproductive choices of all shapes and sizes?” the flier had read, posted online in early April. “Become an abortion doula.” More than 50 women had seen the flier on Facebook or Twitter and responded to the email address at the bottom, not entirely sure what an abortion doula was. Twenty-five had been selected for a weekend-long training at a Virginia abortion clinic, and now, one Saturday morning in May, they’d arrived to see whether they were right for the work. (Hesse, 11/28)